March 30, 2015 - 06:05 AM
BRILINTA® (ticagrelor) now the only P2Y12 inhibitor
with an FDA approved crushing option for administration
Read More
March 14, 2015 - 08:24 AM
Data from 21,000 patient study presented at American College of
Cardiology 64th Annual Scientific Session and simultaneously published…
Read More
January 14, 2015 - 04:01 AM
BRILINTA 60mg and 90mg demonstrate statistically significant
reduction in major cardiovascular thrombotic events in patients with a…
Read More
November 21, 2014 - 08:08 AM
$200+ Million Investment to Support Company’s Maturing Biologics
Pipeline
Read More
